Fabio Conforti

8PUBLICATIONS
56CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 15, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.

Carmine Valenza, Yue Zheng, Monica Milano

|Jan 30, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.

Fabio Conforti, Valentina Nekljudova, Isabella Sala

|Oct 31, 2023
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.

Fabio Conforti, Laura Pala, Tommaso De Pas

|Dec 22, 2021
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.

Fabio Conforti, Laura Pala, Isabella Sala

|Oct 27, 2021
Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy.

Matteo Perrino, Tommaso De Pas, Silvia Bozzarelli

|May 21, 2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.

Fabio Conforti, Laura Pala, Eleonora Pagan

Pageof 2

Frequent Collaborators

4 joint publications

Tommaso De Pas

4 joint publications

Vincenzo Bagnardi

4 joint publications

Richard Gelber

3 joint publications

Laura Pala